The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | Quadruplet regimens for patients with transplant-ineligible multiple myeloma
Meral Beksac, MD, PhD, Ankara University, Ankara, Turkey, discusses treatment options for patients with transplant-ineligible multiple myeloma (MM). While stem cell transplantation (SCT) is the gold standard, emerging data supports the efficacy of quadruplet regimens for those who cannot undergo SCT. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: BMS, Takeda, Amgen; Advisory Board: Pfizer, Menarini, Janssen; Speakers Bureau: Janssen.
